The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | MPNs: genomic updates from ASH 2020
Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital, University of Paris, Paris, France, highlights the exciting new genomic findings in myeloproliferative neoplasms (MPN) presented at ASH 2020, focusing on the genetic mutations that may drive MPN progression and targets for MPN therapy. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Advisory boards for Novartis, BMS, Abbvie, Geron
